Ginkgo Bioworks Holdings, Inc. (DNA) Financial Ratios
7 years of historical data (2019–2025) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↓
1.13
↓-58% vs avg
5yr avg: 2.69
30Y Low0.7·High7.2
ROE
↑
-51.1%
↓+47% vs avg
5yr avg: -96.3%
30Y Low-180%·High-24%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
DNA Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Ginkgo Bioworks Holdings, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Market Cap | $672M | $461M | $510M | $3.3B | $2.8B | $11.3B | — | — |
| Enterprise Value | $922M | $711M | $416M | $2.6B | $2.0B | $9.8B | — | — |
| P/E Ratio → | -1.83 | — | — | — | — | — | — | — |
| P/S Ratio | 3.95 | 2.71 | 2.24 | 13.07 | 5.94 | 36.02 | — | — |
| P/B Ratio | 1.13 | 0.91 | 0.71 | 3.00 | 1.64 | 7.21 | — | — |
| P/FCF | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
DNA EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 4.18 | 1.83 | 10.27 | 4.11 | 31.16 | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — |
DNA Profitability
Margins and return-on-capital ratios measuring operating efficiency
Ginkgo Bioworks Holdings, Inc. earns an operating margin of -185.3%. Operating margins have expanded from -343.8% to -185.3% over the past 3 years, signaling improving operational efficiency. A negative ROE of -51.1% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 81.5% | 81.5% | 83.0% | 78.5% | 57.3% | 58.7% | 79.6% | 100.0% |
| Operating Margin | -185.3% | -185.3% | -246.5% | -343.8% | -462.4% | -582.6% | -178.8% | -132.1% |
| Net Profit Margin | -183.8% | -183.8% | -240.9% | -355.1% | -440.6% | -583.1% | -165.2% | -220.2% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| ROE | -51.1% | -51.1% | -60.3% | -63.0% | -127.4% | -179.6% | -26.1% | -23.8% |
| ROA | -25.0% | -25.0% | -36.0% | -42.5% | -91.3% | -133.3% | -18.4% | -17.1% |
| ROIC | -34.3% | -34.3% | -82.8% | -103.3% | -366.7% | -1870.1% | -157.9% | -224.4% |
| ROCE | -27.5% | -27.5% | -40.4% | -44.7% | -102.7% | -144.1% | -21.8% | -10.9% |
DNA Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
Net debt stands at $250M ($417M total debt minus $167M cash).
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.82 | 0.82 | 0.65 | 0.22 | 0.25 | 0.01 | 0.04 | 0.03 |
| Debt / EBITDA | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | 0.49 | -0.13 | -0.64 | -0.50 | -0.97 | -0.77 | -0.95 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | -5823.55 | -9600.51 | -20012.20 | -773.60 | -51.34 | -48.50 |
DNA Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Ginkgo Bioworks Holdings, Inc.'s current ratio of 4.92x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has declined from 6.11x to 4.92x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Current Ratio | 4.92 | 4.92 | 5.62 | 6.11 | 8.38 | 12.79 | 5.83 | 12.77 |
| Quick Ratio | 4.92 | 4.92 | 5.62 | 6.11 | 8.36 | 12.76 | 5.70 | 12.77 |
| Cash Ratio | 4.40 | 4.40 | 5.24 | 5.76 | 7.61 | 11.50 | 5.20 | 12.36 |
| Asset Turnover | — | 0.15 | 0.16 | 0.15 | 0.19 | 0.15 | 0.11 | 0.08 |
| Inventory Turnover | — | — | — | 1174.02 | 46.80 | 38.58 | 1.68 | — |
| Days Sales Outstanding | — | 51.54 | 36.08 | 25.98 | 64.20 | 174.34 | 104.30 | 51.72 |
DNA Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Ginkgo Bioworks Holdings, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.2% | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.2% | — | — |
| Shares Outstanding | — | $55M | $52M | $49M | $42M | $34M | $32M | $29M |
Peer Comparison
Compare DNA with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 DNAYou | $672M | -1.8 | — | — | 81.5% | -185.3% | -51.1% | -34.3% | — |
 BEAM | $3B | -38.9 | — | — | 84.0% | -274.6% | -8.1% | -31.1% | — |
 TWST | $4B | -45.0 | — | — | 50.7% | -36.2% | -16.4% | -26.9% | — |
 SRPT | $2B | -2.9 | — | — | 59.9% | -29.9% | -53.5% | -31.4% | — |
 CDNA | $1B | -53.6 | — | 30.7 | 67.0% | -5.5% | -6.3% | -5.7% | — |
 CRSP | $5B | -8.1 | — | — | -6537.0% | -16191.4% | -30.2% | -22.3% | — |
 NTLA | $2B | -3.6 | — | — | 76.5% | -651.7% | -53.5% | -44.0% | — |
 EDIT | $297M | -1.7 | — | — | — | — | -198.1% | — | — |
 FATE | $280M | -2.1 | — | — | — | -2222.4% | -51.8% | -36.5% | — |
 ILMN | $21B | 25.5 | 19.6 | 22.6 | 66.7% | 19.9% | 33.4% | 16.8% | 2.3 |
 TMO | $176B | 26.8 | 19.0 | 28.0 | 37.7% | 18.2% | 13.1% | 7.5% | 3.8 |
| Healthcare Median | — | 22.3 | 14.4 | 18.5 | 63.9% | -5.2% | -33.7% | -11.2% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 7 years · Updated daily
See DNA's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs DNA Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare DNA vs BEAM
Side-by-side business, growth, and profitability comparison vs Beam Therapeutics Inc..
Start ComparisonDNA — Frequently Asked Questions
Quick answers to the most common questions about buying DNA stock.
What is Ginkgo Bioworks Holdings, Inc.'s P/E ratio?
Ginkgo Bioworks Holdings, Inc.'s current P/E ratio is -1.8x. This places it at the 50th percentile of its historical range.
What is Ginkgo Bioworks Holdings, Inc.'s ROE?
Ginkgo Bioworks Holdings, Inc.'s return on equity (ROE) is -51.1%. The historical average is -75.9%.
Is DNA stock overvalued?
Based on historical data, Ginkgo Bioworks Holdings, Inc. is trading at a P/E of -1.8x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What are Ginkgo Bioworks Holdings, Inc.'s profit margins?
Ginkgo Bioworks Holdings, Inc. has 81.5% gross margin and -185.3% operating margin.